α—FR在肾细胞癌及膀胱癌患者血清中的表达水平及其临床意义

The clinical significance of α- FR expression in serum of patients with renal cell carcinoma and bladder cancer

目的探讨α-FR（仪型叶酸受体）在肾细胞癌及膀胱癌患者血清中的表达水平及其临床意义。方法选取在本院经组织病理学确诊的肾细胞癌患者58例和膀胱癌患者42例，选取同期在本院健康体检的志愿者40例作为对照组，比较3组研究对象血清中的α-FR表达水平的差异。比较。肾细胞癌和膀胱癌患者不同病理参数间血清中α-FR表达水平的差异。结果肾细胞癌患者血清中的α-FR表达水平（87．39±47．15）pg／mL和膀胱癌患者血清中的α-FR表达水平（84．52±45．68）pg／mL均高于正常对照组（1．45±0．73）pg／mL，且差异具有统计学意义（P〈0．05）。肾细胞癌和膀胱癌患者血清中的α-FR表达水平无统计学差异（P〉0．05）。肾细胞癌TNM分期为Ⅰ期和Ⅱ期的患者血清中的α-FR表达水平（67．39±39．63）pg／mL低于TNM分期为Ⅲ期和Ⅵ期的患者（125．32±68．22）pg／mL，肾细胞癌高分化的患者血清中的α-FR表达水平（155．29±75．31）pg／mL高于中低分化的患者（78．85±42．68）pg／mL，且差异具有统计学意义（P〈0．05）；膀胱癌TNM分期为Ⅰ期和Ⅱ期的患者血清中的α-FR表达水平（84．71±53．64）pg/mL低于TNM分期为Ⅲ期和Ⅵ期的患者（157．92±88．34）pg/mL，膀胱癌高分化的患者血清中的α-FR表达水平（145．31±65．87）pg／mL高于中低分化的患者（79．64±48．22）pg/mL，且差异具有统计学意义（P〈0．05）。结论血清中α-FR表达水平可作为肾细胞癌和膀胱癌诊断的肿瘤标志物。

Objectives To evaluate the clinical significance of α-FR expression in serum of patients with renal cell carcinoma and bladder cancer. Methods 58 cases of renal cell carcinoma and 42 cases of bladder cancer in our hospital were selected ,40 volunteers in the same period were selected as the control group, the differences of the α- FR expression in the serum of the three groups were compared. The expression levels of α- FR in serum between different pathological parameters in patients with renal cell carcinoma and bladder cancer were compared. Results The α- FR expression levels in serum of patients with renal cell carcinoma（87.39 ± 47.15 ） pg/mL and patients with bladder cancer （ 84.52 ± 45.68 ） pg/mL were higher than those of the normal control group （ 1.45 ± 0. 73 ） pg/mL, and the difference had statistical significance（ P 〈 0.05 ）. There was no significant difference of α-FR expression level in the serum of patients with renal cell carcinoma and bladder cancer（ P 〉 0.05 ）. α- FR expression level of renal cell carcinoma TNM stage Ⅰ and Ⅱ （67.39 ±39.63 ） pg/mL was lower than TNM stage Ⅲ andⅥ （125.32±68.22） pg/mL,α-FR expression of renal cell carcinoma with high differentiation in serum （155.29 ±75.31 ）pg/mL was higher than that in low differentiated patients （ 78.85± 42.68 ） pg/mL, α- FR expression level of bladder cancer TNM stage Ⅰ and Ⅱ of （84.71 ± 53.64 ）pg/mL was lower than TNM stage Ⅲ and Ⅵ （157.92±88.34）pg/mL, α-FR expression of bladder cancer with high differentiation in serum （ 145.31 ± 65.87 ）pg/mL was higher than that in low differentiated patients （79.64 ±48.22）pg/mL. Conclusions The expression level of α-FR in serum can be used as a tumor marker for diagnosis of renal cell carcinoma and bladder cancer.